EML4-ALK融合基因重排对晚期非小细胞肺癌诊断及治疗价值

The Progress in Diagnosis and Treatment of Advanced Non-Small Cell Lung Cancer with EML4-ALK Fusion Gene Rearrangement Positive

肺癌的发病率和死亡率居恶性肿瘤之首,而非小细胞肺癌占所有肺癌的80%以上,研究显示EGFR及ALK是非小细胞肺癌的主要驱动基因,针对这两个靶点的靶向药物近年来取得了明显的疗效,受到了广泛关注,本文针对EML4-ALK融合基因重排阳性患者的相关研究进行综述。

Lung cancer is most popular malignant tunors by both morbidity and mortality, non-small cell counts for 80%. Studies have shown that EGFR and ALK are the main driving genes for non-small cell lung cancer. In recent years, targeted drugs targeting these two targets have achieved remarkable curative effect and have been widely concerned. In this paper, we reviewed the related studies of EML4-ALK fusion gene rearranged positive patients.